Regulated cell death pathways in doxorubicin-induced cardiotoxicity.
Effimia ChristidiLiam R BrunhamPublished in: Cell death & disease (2021)
Doxorubicin is a chemotherapeutic drug used for the treatment of various malignancies; however, patients can experience cardiotoxic effects and this has limited the use of this potent drug. The mechanisms by which doxorubicin kills cardiomyocytes has been elusive and despite extensive research the exact mechanisms remain unknown. This review focuses on recent advances in our understanding of doxorubicin induced regulated cardiomyocyte death pathways including autophagy, ferroptosis, necroptosis, pyroptosis and apoptosis. Understanding the mechanisms by which doxorubicin leads to cardiomyocyte death may help identify novel therapeutic agents and lead to more targeted approaches to cardiotoxicity testing.
Keyphrases
- cell death
- high glucose
- cancer therapy
- drug delivery
- cell cycle arrest
- drug induced
- oxidative stress
- end stage renal disease
- diabetic rats
- endothelial cells
- endoplasmic reticulum stress
- transcription factor
- chronic kidney disease
- newly diagnosed
- ejection fraction
- angiotensin ii
- prognostic factors
- peritoneal dialysis
- signaling pathway
- density functional theory